NCCN 2016

The National Comprehensive Cancer Network's 21st annual conference, Advancing the Standard of Care, brings together oncologists from community and academic settings, as well as oncology fellows, nurses, and other cancer care professionals. Opinion leaders present updates on the latest cancer therapies as well as selected NCCN Clinical Practice Guidelines, including the data on which they are based. The conference meets at The Diplomat in Hollywood, Florida, March 31 through April 2, 2016.

Coverage

   |    NCCN 2016 > Surabhi Dangi-Garimella, PhD
Four panelists and 2 moderators discussed the issues surrounding cancer and healthcare in the lead-up to the 2016 presidential election during the National Comprehensive Cancer Network 21st Annual Conference.
Dr John Thompson Outlines Updates in Melanoma
   |    NCCN 2016
John A. Thompson, MD, co-director of the Melanoma Clinic at the Seattle Cancer Care Alliance, highlighted the major points of his melanoma talk at the National Comprehensive Cancer Network’s 21st Annual Meeting, including the FDA approval of new drugs and the development of new viral therapies.
Dr Lee Schwartzberg on Updates in Managing Breast Cancer in Older Women
   |    NCCN 2016
There are a number of lessons oncologists have learned as the population of women who were diagnosed with breast cancer at a younger age grow older, said Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.
   |    NCCN 2016 > Surabhi Dangi-Garimella, PhD
At the National Comprehensive Cancer Network (NCCN) 21st Annual Conference, Alan P. Venook, MD, professor of Clinical Medicine at the University of California, San Francisco, provided insight into lessons learned by oncologists in the treatment of colorectal cancer.
Dr Pamela Becker Says the US Is
   |    NCCN 2016
Now that 1 biosimilar has made it to market in the United States, Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine, expects more to follow and that, hopefully, biosimilars will help achieve cost savings for healthcare.
Dr Robert Carlson on Calculating Value in Cancer Care
   |    NCCN 2016
Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network (NCCN), discussed calculating value in cancer care and the dimensions of NCCN's value assessment framework, Evidence Blocks.
   |    NCCN 2016 > Surabhi Dangi-Garimella, PhD
At the National Comprehensive Cancer Network (NCCN)'s 21st Annual Conference, Robert Carlson, MD, chief executive officer, NCCN, provided a flavor for their value framework, the Evidence Blocks.
   |    NCCN 2016 > Surabhi Dangi-Garimella, PhD
While these “generic” biologicals have been deemed to have the potential to create competition and result in healthcare savings—although not to the extent of generic products—technical issues with manufacturing these products have troubled drug manufacturers.
Compendia
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium
Upcoming Partner Events
June 15-16, 2017
Philadelphia, PA
August 16-17, 2017
Philadelphia, PA
October 24-25, 2017
San Francisco, CA
$vacMongoViewPlus$